<p>MENLO PARK, Calif.–(BUSINESS WIRE)–Geron Corporation (Nasdaq:GERN) today announced the presentation of research studies indicating that GRNCM1, the company’s human embryonic stem cell (hESC)-based therapeutic for the treatment of heart failure, evades direct attack by…</p>